Mast Therapeutics, Inc. (MSTX)

[lux1]

Are there other chances left which aren't external to Mast?
Mast alone means to go bankrupt by 2018.
Since 2013 Mast needed a partnership for Vepo, but this was impossible due to the poor clarity of effectiveness.
Now Mast has 2 P2 close to the end and another bigger started in August with NIH.These tests are sponsored and few expensive for the Co. early results look good and innovative even as market potential.
The Ceo should plan a partnership to start a P3 in 2017. Something similar to that Aires did with Novartis: some cash to start,then on milestones or on interim and sales-rights or right to buy. Aires Therapeutics that developed AIR001, before the business reorganization of Novartis, entered into a contract with this big Pharma for $20M in a P2 for PAH(Pulmonary Arterial Hypertension) and up to $250M of rights of sale.
AIR001 is tested by mast both in PAH and in HFpEF,then market even bigger. Let us hope the CEO ability for once is equal to the task.